PharmaResearch filed its patent in China after its filing in South Korea with consideration to enter global bone disease markets.
PharmaResearch (CEO Shin-kyu Kim, Ki-seok Kang) announced on April 22nd that application for patent registration on bone graft composition using nucleic acid has been granted in China.
The patent is entitled "Bone grafting kit to manufacture nucleic acid, bone graft material and composition for bone-grafting use".
Main characteristics of this kit is to promote the fixability of bone graft material within the area of bone defect and at the same time improving the convenience of surgical procedure with outstanding cohesiveness.
With patent already registered in South Korea, this technology is effectively utilized in many bone-related disease as it can be applied in various areas and types depending on the operator's preferences. It is expected that patent registration in China will play a vital role in diversifying the treatment of bone diseases.
"I am happy that this patented technology can be finally used to treat bone diseases in China," said an official at PharmaResearch. "We will stay committed in expanding patent registration beyond China and eventually penetrate global markets."
PharmaResearch is a biopharmaceutical company with commitments in the production and sales of regenerative medicine, medical devices, cosmetics and health supplements based on tissue regeneration substances, DOT(TM) PDRN and DOT(TM) PN. Main products include Rejuran®, Conjuran®, Rejuran Cosmetics and Re-An® eye drops.
PharmaResearch Co Ltd, formerly Pharma Research Products Co Ltd, is a Korea-based company principally engaged in the manufacturing and distribution of pharmaceuticals. The Company produces and sells regenerated products such as pharmaceuticals, medical devices, and cosmetics. In addition, the Company is involved in the venture investment and real estate leasing. The Company mainly provides its products in domestic market.
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
